Prevention and Early Management of Rash in HR+/HER2-Negative Advanced Breast Cancer

In this segment, Dr. Neil Iyengar moderates a discussion focused on the prevention and early management of dermatologic adverse events associated with PI3K and AKT pathway inhibitors in HR+/HER2-negative advanced breast cancer. Sarah Donahue, MPH, NP, AOCNP outlines the importance of baseline skin assessment prior to treatment initiation, including evaluation of preexisting dermatologic conditions and patient education on daily skincare practices. She emphasizes proactive counseling around gentle cleansers, moisturization, sun protection, and early symptom reporting. The conversation then transitions to a pharmacy perspective, with Heather Moore, CPP, PharmD discussing how expert consensus recommendations are operationalized in clinical workflows. She describes the use of non-sedating H1 antihistamine prophylaxis, BSA-guided topical therapies, and criteria for timely dermatology referral in patients with persistent or worsening rash. This segment highlights how coordinated preventive strategies and early intervention can reduce rash severity, improve patient comfort, and support continued treatment.